Voyager Therapeutics Net Worth
Voyager Therapeutics Net Worth Breakdown | VYGR |
Voyager Therapeutics Net Worth Analysis
Voyager Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Voyager Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Voyager Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Voyager Therapeutics' net worth analysis. One common approach is to calculate Voyager Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Voyager Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Voyager Therapeutics' net worth. This approach calculates the present value of Voyager Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Voyager Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Voyager Therapeutics' net worth. This involves comparing Voyager Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Voyager Therapeutics' net worth relative to its peers.
To determine if Voyager Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Voyager Therapeutics' net worth research are outlined below:
| Voyager Therapeutics had very high historical volatility over the last 90 days | |
| About 66.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Voyager Therapeutics, Inc. Receives 17.00 Consensus PT from Brokerages - MarketBeat |
Voyager Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Voyager Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Voyager Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Voyager Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Voyager Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Voyager Therapeutics backward and forwards among themselves. Voyager Therapeutics' institutional investor refers to the entity that pools money to purchase Voyager Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Federated Hermes Inc | 2024-09-30 | 551.4 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 540.7 K | Bank Of America Corp | 2024-09-30 | 531.6 K | Vestal Point Capital Lp | 2024-09-30 | 490 K | Prudential Financial Inc | 2024-09-30 | 412.4 K | Northern Trust Corp | 2024-09-30 | 406.4 K | Goldman Sachs Group Inc | 2024-09-30 | 328.3 K | Globeflex Capital, L.p. | 2024-09-30 | 291.3 K | Renaissance Technologies Corp | 2024-09-30 | 278.7 K | Blackrock Inc | 2024-06-30 | 5.3 M | Armistice Capital, Llc | 2024-09-30 | 5.2 M |
Follow Voyager Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 314.1 M.Project Voyager Therapeutics' profitablity
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.56) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.56.When accessing Voyager Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Voyager Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Voyager Therapeutics' profitability and make more informed investment decisions.
Evaluate Voyager Therapeutics' management efficiency
Voyager Therapeutics has return on total asset (ROA) of 0.0157 % which means that it generated a profit of $0.0157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1022 %, meaning that it created $0.1022 on every $100 dollars invested by stockholders. Voyager Therapeutics' management efficiency ratios could be used to measure how well Voyager Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.At Voyager Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 0.0877 | Revenue 163.8 M | Quarterly Revenue Growth 4.338 | Revenue Per Share 2.953 | Return On Equity 0.1022 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Voyager Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Voyager Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Voyager Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Voyager Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 9th of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Voyager Therapeutics Earnings per Share Projection vs Actual
Voyager Therapeutics Corporate Management
| Sandrock MD | CEO Pres | Profile | |
| Dr MBA | Chief Officer | Profile | |
| JD Esq | Chief Officer | Profile | |
| Todd Carter | Chief Officer | Profile |
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.